AVITA Medical Reports Mixed Q4, Strong Full-Year 2025 Results, Guides for 12-19% Revenue Growth in 2026

summarizeSummary

AVITA Medical reported a slight Q4 2025 revenue decline but achieved 11% full-year revenue growth within guidance, alongside improved net loss and cash efficiency, and provided positive 2026 revenue guidance.

check_boxKey Events

• Q4 2025 Revenue Decline

  Total revenue for the fourth quarter of 2025 was $17.6 million, a 4% decrease compared to $18.4 million in Q4 2024, attributed to lingering reimbursement headwinds.

• Full Year 2025 Revenue Growth

  Full year 2025 total revenues increased by 11% to $71.6 million, up from $64.3 million in 2024, falling within the company's revised guidance.

• Improved Profitability and Cash Efficiency

  Net loss improved to $11.6 million in Q4 2025 (from $11.6M in Q4 2024) and significantly for the full year to $48.6 million (from $61.8M in 2024). Net cash use improved for the second consecutive quarter to approximately $5.1 million.

• Positive 2026 Revenue Guidance

  The company expects full year 2026 revenue to be in the range of $80 million to $85 million, representing growth of approximately 12% to 19% over 2025.

auto_awesomeAnalysis

AVITA Medical's latest earnings report presents a mixed but generally positive outlook. While fourth-quarter revenue saw a slight year-over-year decline, full-year 2025 revenue grew by 11% and met revised guidance. Crucially, the company demonstrated improved financial discipline, reducing its net loss and significantly improving cash efficiency for the second consecutive quarter. The positive 2026 revenue guidance, projecting 12% to 19% growth, indicates management's confidence in future performance. This report also provides further details on the recently secured $60 million credit facility from Perceptive Advisors, which was previously disclosed on January 13, 2026, and is vital for strengthening the company's capital structure and supporting its growth initiatives, especially as reimbursement headwinds ease.